Concise Overview of Glypromate Neuropeptide Research: From Chemistry to Pharmacological Applications in Neurosciences

Overview

Journal ACS Chem Neurosci

Publisher American Chemical Society

Specialty Neurology

Date 2023 Feb 3

PMID 36735764

Authors

Sara C Silva-Reis

Ivo E Sampaio-Dias

Vera M Costa

Xavier Cruz Correia

Hugo F Costa-Almeida

Xerardo Garcia-Mera

Jose E Rodriguez-Borges

Affiliations

Soon will be listed here.

Abstract

Neurodegenerative diseases of the central nervous system (CNS) pose a serious health concern worldwide, with a particular incidence in developed countries as a result of life expectancy increase and the absence of restorative treatments. Presently, treatments for these neurological conditions are focused on managing the symptoms and/or slowing down their progression. As so, the research on novel neuroprotective drugs is of high interest. Glypromate (glycyl-l-prolyl-l-glutamic acid, also known as GPE), an endogenous small peptide widespread in the brain, holds great promise to tackle neurodegenerative diseases such as Parkinson's, Alzheimer's, and Huntington's, s well as other CNS-related disorders like Rett and Down's syndromes. However, the limited pharmacokinetic properties of Glypromate hinder its clinical application. As such, intense research has been devoted to leveraging the pharmacokinetic profile of this neuropeptide. This review aims to offer an updated perspective on Glypromate research by exploring the vast array of chemical derivatizations of more than 100 analogs described in the literature over the past two decades. The collection and discussion of the most relevant structure-activity relationships will hopefully guide the discovery of new Glypromate-based neuroprotective drugs.

Citing Articles

Trofinetide approved for children and adults with Rett syndrome (RTT): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG).

Selvam P, Mares Beltran C, Sen K, Corado A Genet Med Open. 2024; 2:101856.

PMID: 39669590 PMC: 11613567. DOI: 10.1016/j.gimo.2024.101856.

Discovery of hybrid Glypromate conjugates with neuroprotective activity against paraquat-induced toxicity.

Silva-Reis S, Costa V, da Silva D, Pereira D, Correia X, Garcia-Mera X RSC Med Chem. 2024; .

PMID: 39290380 PMC: 11403921. DOI: 10.1039/d4md00584h.

Reduction in Hippocampal Amyloid-β Peptide (Aβ) Content during Glycine-Proline-Glutamate (Gly-Pro-Glu) Co-Administration Is Associated with Changes in Inflammation and Insulin-like Growth Factor (IGF)-I Signaling.

Frago L, Burgos-Ramos E, Rodriguez-Perez M, Canelles S, Arilla-Ferreiro E, Argente J Int J Mol Sci. 2024; 25(11).

PMID: 38891902 PMC: 11172028. DOI: 10.3390/ijms25115716.

Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need.

Hudu S, Elmigdadi F, Qtaitat A, Almehmadi M, Alsaiari A, Allahyani M J Clin Med. 2023; 12(15).

PMID: 37568516 PMC: 10420089. DOI: 10.3390/jcm12155114.

Trofinetide: a pioneering treatment for Rett syndrome.

Parent H, Ferranti A, Niswender C Trends Pharmacol Sci. 2023; 44(10):740-741.

PMID: 37460385 PMC: 10529922. DOI: 10.1016/j.tips.2023.06.008.

References

Vaaga C, Tovar K, Westbrook G . The IGF-derived tripeptide Gly-Pro-Glu is a weak NMDA receptor agonist. J Neurophysiol. 2014; 112(6):1241-5. PMC: 4137256. DOI: 10.1152/jn.00290.2014. View

Burgos-Ramos E, Martos-Moreno G, Lopez M, Herranz R, Aguado-Llera D, Egea J . The N-terminal tripeptide of insulin-like growth factor-I protects against beta-amyloid-induced somatostatin depletion by calcium and glycogen synthase kinase 3 beta modulation. J Neurochem. 2009; 109(2):360-70. DOI: 10.1111/j.1471-4159.2009.05980.x. View

Lu X, Chen R, Yao C, Wei H, Yang X, Liao Z . NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury. J Neurotrauma. 2009; 26(1):141-54. DOI: 10.1089/neu.2008.0629. View

Qiu J, Zhang R, Li J, Sang Y, Tang W, Rivera Gil P . Fluorescent graphene quantum dots as traceable, pH-sensitive drug delivery systems. Int J Nanomedicine. 2015; 10:6709-24. PMC: 4630193. DOI: 10.2147/IJN.S91864. View

Ferreira da Costa J, Caamano O, Fernandez F, Garcia-Mera X, Sampaio-Dias I, Manuel Brea J . Synthesis and allosteric modulation of the dopamine receptor by peptide analogs of L-prolyl-L-leucyl-glycinamide (PLG) modified in the L-proline or L-proline and L-leucine scaffolds. Eur J Med Chem. 2013; 69:146-58. DOI: 10.1016/j.ejmech.2013.08.001. View

Guan J, Bennet L, Gluckman P, Gunn A . Insulin-like growth factor-1 and post-ischemic brain injury. Prog Neurobiol. 2003; 70(6):443-62. DOI: 10.1016/j.pneurobio.2003.08.002. View

Glaze D, Neul J, Percy A, Feyma T, Beisang A, Yaroshinsky A . A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome. Pediatr Neurol. 2017; 76:37-46. DOI: 10.1016/j.pediatrneurol.2017.07.002. View

Alonso De Diego S, Gutierrez-Rodriguez M, Perez de Vega M, Casabona D, Cativiela C, Gonzalez-Muniz R . New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2005; 16(5):1392-6. DOI: 10.1016/j.bmcl.2005.11.040. View

Guan J . Insulin-like growth factor-1 and its derivatives: potential pharmaceutical application for ischemic brain injury. Recent Pat CNS Drug Discov. 2008; 3(2):112-27. DOI: 10.2174/157488908784534630. View

10.

Arora T, Caviedes P, Sharma S . Effects of a Tripeptide on Mitogen-Activated Protein Kinase and Glycogen Synthase Kinase Activation in a Cell Line Derived from the Foetal Hippocampus of a Trisomy 16 Mouse: an Animal Model of Down Syndrome. Neurotox Res. 2019; 37(3):714-723. DOI: 10.1007/s12640-019-00130-x. View

11.

Olsson M, Nikkhah G, Bentlage C, Bjorklund A . Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci. 1995; 15(5 Pt 2):3863-75. PMC: 6578238. View

12.

Guan J, Harris P, Brimble M, Lei Y, Lu J, Yang Y . The role for IGF-1-derived small neuropeptides as a therapeutic target for neurological disorders. Expert Opin Ther Targets. 2015; 19(6):785-93. DOI: 10.1517/14728222.2015.1010514. View

13.

Marinelli L, Fornasari E, Di Stefano A, Turkez H, Genovese S, Epifano F . Synthesis and biological evaluation of novel analogues of Gly-l-Pro-l-Glu (GPE) as neuroprotective agents. Bioorg Med Chem Lett. 2018; 29(2):194-198. DOI: 10.1016/j.bmcl.2018.11.057. View

14.

Berry-Kravis E, Horrigan J, Tartaglia N, Hagerman R, Kolevzon A, Erickson C . A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome. Pediatr Neurol. 2020; 110:30-41. DOI: 10.1016/j.pediatrneurol.2020.04.019. View

15.

Sun X, Liu Z, Welsher K, Robinson J, Goodwin A, Zaric S . Nano-Graphene Oxide for Cellular Imaging and Drug Delivery. Nano Res. 2010; 1(3):203-212. PMC: 2834318. DOI: 10.1007/s12274-008-8021-8. View

16.

Cacciatore I, Cornacchia C, Baldassarre L, Fornasari E, Mollica A, Stefanucci A . GPE and GPE analogues as promising neuroprotective agents. Mini Rev Med Chem. 2011; 12(1):13-23. DOI: 10.2174/138955712798868995. View

17.

Guan J, Thomas G, Lin H, Mathai S, Bachelor D, George S . Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats. Neuropharmacology. 2004; 47(6):892-903. DOI: 10.1016/j.neuropharm.2004.07.002. View

18.

Korsching S, Auburger G, Heumann R, Scott J, Thoenen H . Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. EMBO J. 1985; 4(6):1389-93. PMC: 554356. DOI: 10.1002/j.1460-2075.1985.tb03791.x. View

19.

Yudin A . Macrocycles: lessons from the distant past, recent developments, and future directions. Chem Sci. 2017; 6(1):30-49. PMC: 5424464. DOI: 10.1039/c4sc03089c. View

20.

Minelli A, Conte C, Cacciatore I, Cornacchia C, Pinnen F . Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model. Amino Acids. 2012; 43(3):1359-67. DOI: 10.1007/s00726-011-1210-x. View